Close Menu

Genetic Technologies

The test is designed to assess the risk of a person developing severe disease if they contract COVID-19 based on a combination of genetic and clinical factors.

The company said it had signed definitive agreements to sell $6.6 million of its American Depository Shares to undisclosed institutional investors.

The Australian molecular diagnostics firm had stockholders' equity in excess of $2.5 million as of Aug. 28, in compliance with the Nasdaq listing rule.

News items for in vitro diagnostics industry for the week of July 20, 2020.

The Australian molecular diagnostics firm said it has signed agreements sell 1,025,000 of its American Depository Shares to several institutional investors.

News items for the in vitro diagnostics industry for the week of May 25, 2020.

The company plans to use the proceeds for general product R&D, for reimbursement studies in the US, and for preparation for potential COVID-19 testing.

News items for the in vitro diagnostics industry for the week of April 20, 2020. 

The funds will be used to launch new products in the US, as well as for R&D activities including the development of polygenic risk tests with partner TGen.

News items for the in vitro diagnostics industry for the week of April 6, 2020.

Pages